OCRA has awarded 400 grants and invested $128 million in ovarian cancer and related gynecologic cancer research initiatives, becoming the largest global charity devoted to ovarian and related gynecologic cancer research in the world.
OCRA has awarded 400 grants and invested $128 million in ovarian cancer and related gynecologic cancer research initiatives, becoming the largest global charity devoted to ovarian and related gynecologic cancer research in the world.
Our commitment to cutting-edge research has resulted in scientific breakthroughs that are igniting hope worldwide and galvanizing top researchers as never before.
OCRA is proud to support groundbreaking ovarian cancer and related gynecologic cancer research. With an annual grantmaking budget of over $7 million, we fund scientists at all stages of their careers. OCRA-funded scientists are working in areas ranging from AI and basic science to clinical and translational research. They are also exploring disease at the cellular and molecular level.
Our researchers come from across the country and around the globe. While their areas of research may differ, they are united in their passion to find a cure and their desire to collaborate and innovate to improve the lives of patients.
OCRA’s new research partnership, The Edmée Firth Fund for Research in Ovarian Cancer (EFFROC), is funding research to develop clinical testing methods and education to increase physicians’ awareness of the disease and the importance of early detection. It is also funding research into ways to reduce the toxicity and side effects of second-line treatments and to improve targeted therapies.
Ovarian Cancer Research Alliance is proud to support five outstanding scientists through our Early Career Investigator Grants, part of the $6 million in new research OCRA is funding in 2025. These … Continued
OCRA is proud to announce the first three recipients of the $6 million we have awarded to support groundbreaking ovarian and related gynecologic cancer research in 2025. And we’re not … Continued
Rates of cervical precancer dropped nearly 80% between 2008 and 2022 among screened women aged 20 to 24, according to the latest Morbidity and Mortality Weekly Report from Centers for Disease … Continued
Get email updates about research news, action alerts, and ways to join the fight.
